Last reviewed · How we verify

NCT05468476

Multi-omics Analysis of Women With PCOS and Obesity Compared With Non-PCOS Obese Controls

Completed Last updated 1 May 2023
What this trial tests

trial testing No intervention in Polycystic Ovary Syndrome in 121 participants. Completed in 31 December 2022.

Timeline
1 May 2019
Primary endpoint
31 August 2022
31 December 2022

Quick facts

Lead sponsorZhang Manna
StatusCompleted
Study typeOBSERVATIONAL
Enrollment121
Start date1 May 2019
Primary completion31 August 2022
Estimated completion31 December 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhang Manna

Who can join

Adults 18 to 45, female only, with Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in reproductive-aged women, which associated with increased risks to develop metabolic disorders, including cardiovascular diseases, diabetes mellitus, and cerebrovascular diseases. The precise pathogenesis of PCOS remains unknown but is thought to be multifactorial, comprising genetic and environmental factors .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

Other Zhang Manna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05468476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing